Zumutor Biologics Inc.

Kavitha Iyer Rodrigues

Vivek Halan

Maloy Ghosh

Sanghamitra Bhattacharjee

Sunit Maity

Bharath Ravindra Shenoy

Sahana Bhima Rao

Divya Unnikrishnan

Anuradha Hora

Bhargav Prasad

Sohang Chatterjee

Karthika Nair

Sankaranarayanan Srinivasan

Aswini Thanigaivel

Yogendra Manjunath Bangalore Muniraju

Sathyabalan Murugesan

Bairavabalakumar Natarajan

Amol Maliwalave

Subhra Prakash Chakrabarty

Ashvini Kumar Dubey

Anurag Tiwari

Amir Khan

Pravin Kumar Dakshinamurthy

Pavithra Mukunda

Veeresha Kamanagowda

Santosh Kumar

Pavithra M

Nikitha Markanda

Pravin Kumar D

Sathyabalan M

Yogendra Manjunath B M

Veeresha K

Bairavabalakumar N

Shivani Patel

Rajeshwari Pendse

Prabhat Kumar Pathak

Anisha Kurup

Jahnabi Hazarika

Ankurina Sharma

Nikitha M

Rao Shreesha Ramesh

Rashmi Sharma

Jahnabi Arika

Pallavi Lahiri

Shruti Srivastava

Bhagyashree Dikey

Kirthana Mysore Vasudevarao Sindhe

Prachi

Maliwalave Amol

Yogendra Manjunath Muniraju

Sankarnarayanan Srinivasan

The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.

Antibodies that bind to C-type lectin domain family 2 member D (CLEC2D)

The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.

Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)

The present disclosure relates to a method of obtaining a cell where fucosylation pathways are modified, leading to production of partially fucosylated and non-fucosylated protein products, specifically antibodies from the cell. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. The method of the present disclosure targets the Fut8 gene and GMD gene in a cell. Such products are used in developing therapeutics and biomarkers, and in diagnosis and prognosis of diseases.

DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof

The present disclosure relates to vectors for cloning and expressing genetic material including but not limiting to antibody gene or parts thereof and methods of generating said vectors. Said vectors express the antibody genes in different formats such as Fab or scFv as a part of intertransfer system, intratransfer system or direct cloning and expression in individual display systems. In particular, phage display technology is used to clone and screen potential antibody genes in phagemid which is followed by the transfer of said genes to yeast vector for further screening and identification of lead molecules against antigens. The present vectors have numerous advantages including uniquely designed inserts/expression cassettes resulting in efficient and smooth transfer of clonal population from phage to yeast vectors resulting in efficient library preparation and identification of lead molecules.

Vectors for cloning and expression of proteins, methods and applications thereof

The present disclosure relates to a method of generating an antibody library, not limiting to a human na&#xef;ve antibody gene expression library encompassing a pool of nucleic acid sequences derived from a natural antibody repertoire comprising humoral immunity from healthy and genetically diverse human populations. More specifically, the method employs a combination of phage and/or yeast antibody surface display concept which allows to screen large antibody library size and facilitates better folding of antibody structure. The present disclosure also relates to a human na&#xef;ve antibody library generated by employing the process of the present disclosure, a set of primers employed in the method and application(s) of said antibody library.

Method of generating an antibody na&#xef;ve library, said library and application(s) thereof

The present disclosure relates to methods of obtaining cell with disrupted fucosylation and obtaining afucosylated protein. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology in a protein producing cell line to produce afucosylated protein. The resulting protein, specifically the resulting monoclonal antibody is completely afucosylated and reveals higher degree of antibody dependent cellular cytotoxicity.

Afucosylated protein, cell expressing said protein and associated methods

The present disclosure relates to a method of generating an antibody library, not limiting to a synthetic antibody gene expression library built on pool of consensus nucleic acid sequences by using codon replacement technology. The present disclosure also relates to a synthetic antibody library generated by employing the method of the present disclosure and application(s) of said antibody library.

Method of generating a synthetic antibody library, said library and application(s) thereof

The present disclosure relates to developing cell lines where specific biological pathways are modified, particularly by modifications in the enzymes of the cell. The present disclosure develops protein expression systems wherein specific modification of glycan chain of the protein is achieved, which produces non-fucosylated proteins, including non-fucosylated antibodies. The non-fucosylated proteins are used in developing therapeutic monoclonal antibodies and biomarkers, and in diagnosis and prognosis of various diseases. The present disclosure employs the Transcription Activator like Effector Nuclease (TALEN) technology for inactivating fucosylation in a cell.

Non-fucosylated protein and methods thereof

Growing community of inventors

Bengaluru, India

Kavitha Iyer Rodrigues